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Abstract 
Study Objectives: The WatchPAT is a wrist-worn portable device that creates integration data 
regarding peripheral arterial tone (PAT), oxyhemoglobin saturation, heart rate, and 
actigraphy to diagnose or screen for obstructive sleep apnea (OSA). Previous studies have 
demonstrated the efficacy and validity of respiratory variables measured by the WatchPAT 
compared to those using polysomnography (PSG). However, the effects of arterial stiffness 
or atherosclerosis on WatchPAT parameters remain to be elucidated. Methods: Sixty-one 
consecutive patients with suspected OSA who underwent home-based testing with the 
WatchPAT 200, standard in-laboratory overnight polysomnography (PSG), and pulse wave 
velocity (PWV) as an index of arterial stiffness were studied. All PSG recordings were scored 
manually using the American Academy of Sleep Medicine criteria, whereas WatchPAT data 
were analyzed by an automatic algorithm. We evaluated how arterial stiffness affected 
respiratory event index data in WatchPAT (WP-AHI), because WP-AHI could be partly 
influenced by PAT, comparing WP-AHI and the apneahypopnea index measured by PSG 
(PSG-AHI) in consideration of PWV result. Results: Overall, WP-AHI was moderately 
correlated to PSG-AHI, but WP-AHI was significantly lower than PSG-AHI (28.4 ± 19.2 
versus 53.6 ± 30.2 events/h, P < .0001). For the lower PWV group, there was a significant 
correlation and good agreement between the WP-AHI and PSG-AHI, but as the PWV 
increased, there was low correlation between the WP-AHI and PSG-AHI. Conclusions: 
Arterial stiffness may affect the respiratory variables measured by WatchPAT in patients with 
OSA. 
 
Introduction 
Obstructive sleep apnea (OSA) is a common sleep-related breathing disorder characterized 
by repetitive complete or partial obstruction of the upper airway during sleep. The diagnosis 
and treatment of OSA are critical to avoid the potential risks of fatal cerebrovascular or 
cardiovascular events, and death from causes mainly related to the atherosclerotic process.1,2 
However, at least 80% of moderate-to-severe OSA remains undiagnosed in middle-aged 
adults.3 The current gold standard for diagnosing OSA is in-laboratory overnight 
polysomnography (PSG),4 but despite providing the most accurate description of sleep 
disorders, it is limited by high costs, long waiting lists in some areas, and the requirement for 
overnight assessment. Therefore, alternative approaches are required. 
The WatchPAT is a wrist-worn ambulatory device that is used to diagnose or screen for 
OSA, and is categorized as a type 3 monitoring device by the American Academy of Sleep 
Medicine (AASM).5 Multiple studies have demonstrated that the respiratory parameters 
calculated using the WatchPAT correlates well with that calculated by full PSG.6–8 In Japan, 
the WatchPAT has mainly been used to screen for OSA. The variables calculated by the 
WatchPAT algorithm are based on peripheral arterial tone (PAT), heart rate, oxyhemoglobin 
saturation, and actigraphy,9 allowing indirect detection of apnea and hypopnea events through 
PAT signal attenuation, heart rate increase, and desaturation.6,10,11 Given that the PAT 
measurement is based on a physiological signal reflecting changes in vascular volume in the 
digit using the finger-mounted plethysmograph,9 an impaired peripheral vascular response 
might affect the respiratory variables measured by the WatchPAT. Indeed, patients using α-
adrenergic receptor-blocking agents cannot be accurately evaluated by WatchPAT, because 
such agents are known to affect the PAT signal.12,13 The role of more common conditions, 
such as arterial stiffness or atherosclerosis, has not been adequately considered in the 
literature. Brachial-ankle pulse wave velocity (baPWV) is a widely used modality for 
evaluating arterial stiffness.14 The baPWV can be noninvasively and indirectly assessed by 
calculating the time that it takes a pulse wave to travel along the vasculature between the 
brachium and ankle. Previous research has shown that baPWV is an independent predictor of 
the presence of coronary artery disease, myocardial injury, and future cardiovascular 
events.15,16 Therefore, we hypothesized that arterial stiffness (ie, a high pulse wave velocity 
[PWV]) would attenuate the accuracy of the respiratory variables measured by WatchPAT. 
In the current study, we investigated the effect of arterial stiffness, as measured by baPWV, 
on WatchPAT variables in patients with OSA. 
 
METHODS 
Study Design We enrolled adult patients with suspected OSA in whom the diagnosis was made 
at Chiba University Hospital between April 2015 and March 2016. Registrations were 
consecutively conducted at each patients’ first visit at the Sleep Disordered Breathing Clinics 
in our hospital (if consent to participating in our study were obtained). Patients with 
suspected other sleep conditions (ie, nongeneral OSA such as heart failure with central sleep 
apnea, narcolepsy, or obvious neuromuscular disease) were not registered. Exclusion criteria 
for the study were history of permanent pacemaker, nonsinus cardiac arrhythmias, and use of 
α-adrenergic receptor-blocking agents or short-acting nitrates (24-hour washout period 
required). Before the study, patients completed a questionnaire concerning daytime 
sleepiness (Epworth Sleepiness Scale), medical history, and physical data (eg, weight and 
height). Patients first underwent home-based portable monitoring using a WatchPAT 200 
(Itamar Medical Ltd., Caesarea, Israel) before visiting the hospital for standard in-laboratory 
full overnight PSG (mean duration between WatchPAT and PSG was 39.1 ± 26.5 days). On 
the same day as the patient underwent PSG, the baPWV was measured. Informed consent 
was obtained from all participants after the protocol was approved by the Institutional Review 
Board of Chiba University Hospital. 
 
Home-Based Testing by WatchPAT 
For home study, patients received instructions on how to use the WatchPAT device. These 
instructions addressed proper application of the device and were accompanied by a 
demonstration of correct use, and lasted 5 to 10 minutes. The WatchPAT is a four-channel, 
unattended, ambulatory monitoring device that records PAT signals, heart rate, oxygen 
saturation, and actigraphy. The WatchPAT calculates clinical parameters such as respiratory 
event index and 4% oxygen desaturation index (ODI) by its automated and proprietary 
algorithm (analyzed data reports are automatically made in the default setting). This device 
is worn around the wrist and has one finger probe that contains a PAT sensor for measuring 
PAT changes in peripheral arterial beds, a heart rate sensor, and an oximetry sensor for 
measuring arterial oxygen saturation. The wrist unit contains the actigraphy sensor for 
measuring wrist movements through a three-dimensional accelerometer. Using the 
WatchPAT software (ZZZ PAT, Itamar Medical Ltd., Caesarea, Israel), the resulting data 
were automatically analyzed to identify respiratory events and sleep states. The automated 
analysis used actigraphy to identify wake-sleep states. Respiratory events were detected as 
follows: (1) termination of respiratory disturbances led to a surge of sympathetic activity that 
influenced peripheral arterial vasoconstriction; (2) vasoconstriction of the peripheral arterial 
bed by alpha receptors resulted in an attenuation of PAT signal; and (3) PAT signal 
attenuation, increased heart rate, and oxygen desaturation were analyzed by the automatic 
computerized algorithm of the WatchPAT system.5 Manual editing of automated scoring is 
possible but was avoided in the current study to allow the assessment of only algorithm 
performance rather than that of the algorithm plus human operator. In addition, a previous 
study demonstrated the validation of automated scoring.5,7 
 
In-Laboratory Testing by Polysomnography 
All patients underwent standard, in-laboratory, full overnight PSG, using an E Series monitor 
(Compumedics, Victoria, Australia). The following were recorded: electroencephalography 
(EEG; C4-M1, O2-M1, C3-M2, O1-M2), electrooculography, submental and bilateral 
anterior tibial electromyography, electrocardiography, respiratory effort by thoracoabdominal 
piezoelectric belts, nasal airflow by nasal pressure cannula, nasal and oral flow by a thermistor, 
finger pulse oximetry, snoring recording by a neck microphone, and assessment of body 
posture by a thoracic belt sensor. The 2007 American Academy of Sleep Medicine alternative 
criteria was used to score the PSG.8 Apnea was defined as a reduction in nasal airflow to < 
10% of the baseline for ≥ 10 seconds. Hypopnea was defined as a reduction in nasal airflow 
signal amplitude of ≥ 50% for ≥ 10 seconds in association with either an oxygen desaturation 
of ≥ 3% or arousal on EEG. OSA was defined as an apnea-hypopnea index (AHI) of ≥ 5 
events/h, combined with predominantly obstructive respiratory events. OSA severity was 
classified according to the AHI, as follows: mild, 5–15; moderate, 15–30; and severe, ≥ 30 
events/h. All PSG tests were scored by a single technician. 
 
Brachial–Ankle Pulse Wave Velocity 
The baPWV was measured in the supine position, using an automated device (Colin form; 
OMRON COLIN Co., Ltd. Tokyo, Japan) that measures arterial pulse waves in both the 
brachial and posterior tibial arteries by the oscillometric method.14 The pressure waveforms 
of the brachial and tibial arteries were obtained from occlusion and monitoring cuffs around 
the upper arm and the ankle. The transmission distance between the brachium and ankle was 
calculated automatically based on the height of the patient.17 The average of the left and right 
values was used for analysis. Several studies have reported the cutoff value of baPWV for 
cardiovascular disease. Maeda et al. compared 3,628 outpatients with diabetes and showed 
baPWV of 1400 cm/s as statistically adequate cutoff points for cardiovascular events and 
mortality.18 Kim et al. reported baPWV > 1700 cm/s was strongly associated with the presence 
and severity of cardiovascular disease.15 Based on these studies, we decided upon a baPWV 
threshold from 1300 cm/s to 1800 cm/s. 
 
Data and Statistical Analysis 
The following data were derived from in-laboratory PSG testing: total sleep time, rapid eye 
movement (REM) sleep, deep non-REM (NREM) sleep, 4% ODI, and AHI (PSG-AHI). The 
following data were derived from the home WatchPAT testing: total sleep time, REM sleep, 
deep NREM sleep, 4% ODI, and respiratory event index (WP-AHI). Demographic variables 
are presented as mean ± standard deviation, unless otherwise stated. Differences between 
the PSG and WatchPAT measurements were compared by paired t tests. Bland-Altman plots 
were used to determine the agreement between PSG and WatchPAT measurements in the 
study groups. Receiver operator characteristic (ROC) curves were constructed to illustrate 
the diagnostic performance of the WP-AHI, which was compared to the reference standard 
(ie, PSG-AHI ≥ 30 events/h for a positive result, and PSG-AHI < 30 events/h for a negative 
result). The area under the ROC curves, and the sensitivity and specificity for WP-AHI cutoff 
values were calculated. Pearson correlation coefficients between the PSG-AHI and WP-AHI 
were calculated; subgroup analyses according to different thresholds of the PWV values (ie, 
1300, 1350, …, 1750, and 1800 cm/s) were also performed to explore the effect of arterial 
stiffness. Values of P < .05 by two-tailed tests were considered to denote statistical 
significance. All statistical analyses were done using JMP Pro Version 12.0 (SAS Institute, 
Cary, North Carolina, United States). 
 
RESULTS 
Participant Characteristics 
Characteristics of the study population are shown in Table 1. A total of 61 patients (48 males, 
13 females) were studied, for whom the average age was 57.1 ± 13.5 years and the body mass 
index was 26.5 ± 4.4 kg/m2. Fifty-four patients (88.5%) had at least one comorbidity other 
than obesity, with the greatest percentages having hypertension (49.2%), diabetes mellitus 
(24.6%), or dyslipidemia (19.7%). All the patients recruited had OSA, with mild OSA in 6.6%, 
moderate OSA in 16.2%, and severe OSA in 77.2%. 
 
 
Comparison of Sleep and Breathing Variables Between PSG and WatchPAT 
The comparison of sleep and respiratory variables between PSG and WatchPAT are shown in 
Table 2. The WP-AHI was significantly lower than the PSG-AHI. Total sleep time, deep 
NREM sleep, and REM sleep were significantly higher in WatchPAT than in PSG. However, 
there was no significant difference in the 4% ODI between the WatchPAT and PSG. The 
Bland-Altman plot illustrated that as PSG-AHI increased, the WatchPAT tended to 
underestimate the respiratory event index, indicating that proportional bias existed in 
respiratory indices between WatchPAT and PSG, as shown in Figure 1. ROC curves for 
respiratory event indices are shown in Figure 2. The area under the curve for PSG-AHI ≥ 30 
events/h was 0.84 (95% confidence interval [CI]: 0.73–0.95, P = .0008). When diagnosis of 
OSA was defined to WP-AHI cutoff values of 18.6 events/h, the sensitivity and specificity for 
the WatchPAT to identify PSGAHI ≥ 30 events/h were 0.79 (95% CI: 0.64–0.89) and 0.80 
(95% CI: 0.44–0.97), respectively. As shown in Figure 3, there was a moderate correlation for 
the respiratory event indices between WatchPAT and PSG (r = .69, P < .0001). 
 
 
  
 
 The Effect of Arterial Stiffness on the Relationship Between WatchPAT and PSG  
To evaluate the effect of arterial stiffness, we compared the correlations between WP-AHI 
and PSG-AHI groups with PWV results lower and higher than the selected PWV (range 1300–
1800 cm/s), as shown in Table 3. In patients with lower PWV values than each cutoff value 
(from 1300 to 1800 cm/s), there were very high correlations for the respiratory event indices 
between the WatchPAT and the PSG groups. Among them, patients with a PWV under 1300 
cm/s has the highest correlation between PSG-AHI and WP-AHI (r = .811, P = .0001). As 
the PWV cutoff value increased, the correlation became lower. Conversely, patients with a 
PWV over 1550 cm/s have no statistical correlation for the respiratory event indices between 
the WatchPAT and the PSG. Figure 4 shows the representative difference classified by a PWV 
of 1500 cm/s (lower; n = 33, r = .78, P < .0001 higher; n = 27, r = .40, P = .04). 
 
 
DISCUSSION 
This is the first study, to our knowledge, to have used baPWV to evaluate how arterial stiffness 
affects the respiratory variables measured by WatchPAT in patients with OSA. We showed 
that overall correlation and agreement were good between WPAHI and PSG-AHI, and that 
this correlation was strongest among patients with low arterial stiffness. By contrast, there 
was low correlation between WP-AHI and PSG-AHI among patients with high arterial 
stiffness. These results indicate that arterial stiffness should be considered, especially in 
patients suspected of arterial stiffness, when evaluating by WatchPAT. The mean WP-AHI 
was also lower than the mean PSG-AHI in this study, suggesting that the WatchPAT may 
underestimate the respiratory event index, partially because of the effect of arterial stiffness. 
 
The Effect of Arterial Stiffness Measured by PWV on WatchPAT Variables 
In the current study, the WP-AHI in the high PWV group had worse correlation with PSG-
AHI than that in the lower group. This indicated that reduction in the extensibility of the 
peripheral arteries due to increased stiffness was related to the estimated number of apnea 
and hypopnea events analyzed by the WatchPAT. Arterial stiffness reflects physiological 
changes in the mechanical and structural properties of the vascular wall that lead to reduced 
arterial compliance. In turn, variation in arterial stiffness has been correlated with 
cardiovascular outcomes, and is an emerging prognostic factor with hypertension, diabetes, 
obesity, and dyslipidemia.19 Given that the PAT is a major component variable in assessments 
using the WatchPAT, it was anticipated that arterial stiffness would affect the related 
respiratory index, especially for patients in clinical settings (eg, diversity of medications, 
complications, age, and OSA severity). Most previous studies of the WatchPAT have excluded 
patients with diabetes mellitus, peripheral neuropathy, vasculopathy, or cardiac disease 
because these diseases may theoretically affect peripheral blood flow.7 Few studies have 
focused on the effect of arterial impairment on results from the WatchPAT. Aging is also 
associated with impaired peripheral vascular tone and can affect the WatchPAT data, but 
Onder et al. demonstrated that aging did not negatively affect the PAT-recorded respiratory 
index.20 However, they did show that there was a significant difference between young and 
old groups in PAT- and PSG-recorded stage N3 sleep.20 This finding may be attributed to 
aging and impaired vascular tone. 
 
WP-AHI Compared With PSG-AHI We also showed that the mean WP-AHI was lower than 
the mean PSG-AHI, even though most studies that validated the WatchPAT demonstrated 
good agreement with PSG for the respiratory event index. This discordance can be explained 
by the differences in study populations. The Brand-Altman plot illustrated that as PSG-AHI 
increased, the WatchPAT tended to underestimate the respiratory event index. Thus, 
consistent with research by other authors,6,21 we observed proportional bias when using the 
WatchPAT in this study. This may be explained, in part, by the fact that the WatchPAT had 
more difficulty detecting individual events when multiple events occurred over a brief 
period.21 It was also notable that our research included patients with severe OSA (mean AHI 
53.6 events/h, and severe OSA in 77%), whereas most previous studies have tended to include 
patients with mild-to-moderate OSA. This important difference in the study population may 
also have caused the results to be underestimated. Given that most symptomatic patients who 
consult their doctor have severe OSA (eg, daytime sleepiness or severe snoring), it is 
important to know that the WatchPAT might underestimate the respiratory variables in these 
patients. 
 
Clinical Implications 
The WatchPAT is a simple and patient-friendly portable device for assessing suspected OSA, 
providing suitably accurate assessment of respiratory disturbance during sleep with minimal 
technical effort and low cost. The device has been widely used in clinical settings and trials 
already (eg, screening in certain diseases and occupations, determination of treatment 
effect).10,22–24 However, our results demonstrated a note of caution that arterial stiffness may 
affect the respiratory index measured by the WatchPAT, and that it might be necessary to 
consider the grade of arterial stiffness when assessing test results using this device. This is 
especially important because, compared with earlier studies, our population was closer to that 
typically seen in clinical settings. Indeed, we included patients with more severe OSA and 
with several comorbidities, including hypertension, diabetes mellitus, and dyslipidemia, 
whereas previous studies of the WatchPAT have mainly included patients with mild-to-
moderate OSA and no comorbidities.7 In real-word clinical situations, we therefore think that 
the WatchPAT might underestimate the respiratory event index when compared with PSG. 
Given this, clinicians might need to assess the merits of the WatchPAT device over full PSG 
before performing an assessment for patients with OSA using WatchPAT. 
 
Limitations 
There are several limitations to our study. First, this study included a small number of patients 
with OSA and it was conducted at a single hospital. Second, there is a possibility of night-to-
night variation because the WatchPAT and PSG assessments were not performed on the same 
nights (the duration between WatchPAT and PSG was 39.1 ± 26.5 days). This may affect 
our results to some extent, whereas our study originally intended to evaluate the efficacy and 
accuracy of home-based WatchPAT in practical use in actual clinical situations (ie, a portable 
modality for use in screening or for the diagnosis of in-home situations) compared to that of 
in-laboratory PSG. However, other studies have demonstrated good correlation for 
respiratory disturbance between the WatchPAT and PSG when recorded on different nights, 
so we do not think that this will have had a major influence on the relationship between the 
WPAHI and PSG-AHI.5,25 Third, in our study, we found that total sleep time was significantly 
longer in WatchPAT than in PSG. Possible reasons include the following: (1) because 
WatchPAT does not monitor EEG, total sleep time may have been underestimated in our 
subjects, and (2) the first-night effect during in-hospital PSG testing may decrease the total 
sleep time (versus home testing). Additionally, regarding longer deep sleep time in 
WatchPAT than that in PSG, O’Brien et al. showed poor relationships in sleep stage 
characteristics between WatchPAT and PSG; in particular, agreement for deep sleep was not 
well achieved.22 In the current study, it remains uncertain whether WatchPAT 
underestimated deep sleep time. Fourth, it should be noted that the baPWV mainly represents 
large arteries, whereas WatchPAT represents peripheral arteries. Nevertheless, baPWV is 
known to be partially influenced by peripheral arteries.26 Activation of α-sympathetic nerves, 
which is essential for detecting the respiratory index when using the WatchPAT, has been 
demonstrated to reduce forearm vascular and fingertip vascular resistance when using α-
adrenergic agonist.13 Therefore, we consider it reasonable to use baPWV to assess arterial 
stiffness as a factor that can change fingertip blood flow. Finally, regarding body mass index 
and Epworth Sleepiness Scale score, the averages of our study were quite low (26.5 ± 4.4 
kg/m2 and 6.2 ± 4.6, respectively) compared to other general previous reports for OSA. We 
believe that this disagreement may be because of population difference (eg, East Asian versus 
Western countries) regardless of the presence of severe OSA. Therefore, some differences 
may exist between our study population and those of others. 
 
CONCLUSIONS  
In conclusion, we have shown that there was a strong correlation between WP-AHI and PSG-
AHI as PWV values decreased, but that there was low or no correlation as PWV increased, 
indicating that arterial stiffness may affect the respiratory event index measured by the 
WatchPAT. The results of the current study suggest exercising caution when using the 
WatchPAT to diagnose OSA in patients with severe arterial stiffness. 
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